VeraDermics, Incorporated was founded on October 5, 2019, originally located in Texas, and was converted to a Delaware company on September 15, 2021. This late-stage clinical-stage biopharmaceutical company, founded by a dermatologist, focuses on developing innovative therapies for prevalent aesthetic and dermatological conditions. VeraDermics focuses on addressing the challenges of patterned alopecia (PHL) treatment that affects numerous individuals in the United States. The Company is currently advancing its lead drug candidate, VDPHL 01, an oral non-hormonal treatment designed to optimize hair growth while minimizing side effects associated with traditional therapies. VeraDermics is conducting pivotal clinical trials to support regulatory approval and, through its targeted treatment approach, aims to change the way PHL is managed.
